» Articles » PMID: 16634078

Developmental Toxicity Evaluation of Berberine in Rats and Mice

Overview
Date 2006 Apr 25
PMID 16634078
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Berberine, a plant alkaloid, is found in some herbal teas and health-related products. It is a component of goldenseal, an herbal supplement. Berberine chloride dihydrate (BCD) was evaluated for developmental toxicity in rats and mice.

Methods: Berberine chloride dihydrate was administered in the feed to timed-mated Sprague-Dawley (CD) rats (0, 3,625, 7,250, or 14,500 ppm; on gestational days [GD] 6-20), and Swiss Albino (CD-1) mice (0, 3,500, 5,250, or 7,000 ppm; on GD 6-17). Ingested doses were 0, 282, 531, and 1,313 mg/kg/day (rats) and 0, 569, 841, and 1,155 mg/kg/day (mice).

Results: There were no maternal deaths. The rat maternal lowest observed adverse effect level (LOAEL), based on reduced maternal weight gain, was 7,250 ppm. The rat developmental toxicity LOAEL, based on reduced fetal body weight per litter, was 14,500 ppm. In the mouse study, equivocal maternal and developmental toxicity LOAELs were 5,250 ppm. Due to scattering of feed in the high dose groups, a gavage study at 1,000 mg/kg/day was conducted in both species.

Conclusions: In rats, maternal, but not fetal adverse effects were noted. The maternal toxicity LOAEL remained at 7,250 ppm (531 mg/kg/day) based on the feed study and the developmental toxicity NOAEL was raised to 1,000 mg/kg/day BCD based on the gavage study. In the mouse, 33% of the treated females died. Surviving animals had increased relative water intake, and average fetal body weight per litter decreased 5-6% with no change in live litter size. The maternal toxicity LOAEL remained at 5,250 ppm (841 mg/kg/day) BCD, based on increased water consumption. The developmental toxicity LOAEL was raised to 1,000 mg/kg/day BCD based on decreased fetal body weight.

Citing Articles

Enhancement of antitumor effects of berberine chloride with a copper(II) complex against human triple negative breast cancer: studies.

Alajroush D, Anderson B, Bruce J, Lartey C, Mathurin D, Washington S Results Chem. 2025; 12.

PMID: 39802841 PMC: 11720871. DOI: 10.1016/j.rechem.2024.101882.


Berberine potentiates liver inflammation and fibrosis in the PI*Z hAAT transgenic murine model.

Lu Y, Mohammad N, Lee J, Aranyos A, Serban K, Brantly M PLoS One. 2024; 19(9):e0310524.

PMID: 39298444 PMC: 11412680. DOI: 10.1371/journal.pone.0310524.


Oxyberberine sensitizes liver cancer cells to sorafenib via inhibiting NOTCH1-USP7-c-Myc pathway.

Sun L, He M, Li F, Wu D, Zheng P, Zhang C Hepatol Commun. 2024; 8(4).

PMID: 38573832 PMC: 10997235. DOI: 10.1097/HC9.0000000000000405.


Clinically Effective Molecules of Natural Origin for Obesity Prevention or Treatment.

Hidalgo-Lozada G, Villarruel-Lopez A, Nuno K, Garcia-Garcia A, Sanchez-Nuno Y, Ramos-Garcia C Int J Mol Sci. 2024; 25(5).

PMID: 38473918 PMC: 10931663. DOI: 10.3390/ijms25052671.


Neuroprotective Properties of Berberine: Molecular Mechanisms and Clinical Implications.

Tian E, Sharma G, Dai C Antioxidants (Basel). 2023; 12(10).

PMID: 37891961 PMC: 10604532. DOI: 10.3390/antiox12101883.